Levels of cerebrospinal fluid (CSF) biomarkers Aβ and tau closely reflect the central pathogenic processes in AD and have proven their utility in evaluating disease risk or prognosis, guiding clinical diagnosis and monitoring therapeutic interventions [1, 2]. The gene discussed is MAPT; the disease is Alzheimer disease.